Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis-Reference-Cited by-同舟云学术

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

Published:2017-04-20 Issue:16 Volume:376 Page:1551-1560
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Papp Kim A.,Blauvelt Andrew,Bukhalo Michael,Gooderham Melinda,Krueger James G.,Lacour Jean-Philippe,Menter Alan,Philipp Sandra,Sofen Howard,Tyring Stephen,Berner Beate R.,Visvanathan Sudha,Pamulapati Chandrasena,Bennett Nathan,Flack Mary,Scholl Paul,Padula Steven J.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1607017

Cited by 439 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Pharmacokinetics of Single‐Dose Mirikizumab in Chinese Healthy Participants: Results From a Phase 1 Study;Clinical Pharmacology in Drug Development;2024-09-04

2. Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a Cochrane systematic review;Journal of Clinical Epidemiology;2024-09

3. Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy;JID Innovations;2024-09

4. Treatment strategies for Spondyloarthritis: Implementation of precision medicine – Or “one size fits all” concept?;Autoimmunity Reviews;2024-09

5. Effectiveness of risankizumab induction and maintenance therapy for refractory Crohn’s disease: a real-world experience from a preapproval access programme and early access to medicines scheme;Frontline Gastroenterology;2024-08-30